DARE Daré Bioscience | $0.30
+3.5% | 4/17/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $1.27
+5.0% | 4/5/2024 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $10.00 | Low | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
FUSN Fusion Pharmaceuticals | $21.25
+0.0% | 3/19/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 3/19/2024 |
ATE Antibe Therapeutics | C$0.30
| 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 3/4/2024 |
ATBPF Antibe Therapeutics | $0.22
| 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $9.88
+9.9% | 2/28/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Buy -> Hold | $9.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
|
OTLK Outlook Therapeutics | $8.29
-3.7% | 1/25/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $31.40 | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 1/25/2024 |
ONCT Oncternal Therapeutics | $8.60
-3.9% | 12/4/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $40.00 | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 12/4/2023 |
LNTH Lantheus | $62.33
+1.4% | 11/30/2023 | Initiated by | Brookline Capital Management | - | Buy | $100.00 | Low | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $9.88
+9.9% | 11/10/2023 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $35.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $3.86
+6.6% | 10/30/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | | Low | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
EYEN Eyenovia | $0.53
-1.8% | 10/17/2023 | Initiated by | Brookline Capital Management | - | Buy | $8.00 | Low | View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 10/17/2023 |
EDSA Edesa Biotech | $4.35
-1.1% | 10/12/2023 | Reiterated by | Brookline Capital Management | - | Buy -> Buy | $57.00 | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
PROC Procaps Group | $2.60
-3.0% | 9/6/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | $4.50 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 9/6/2023 |
OTLK Outlook Therapeutics | $8.29
-3.7% | 8/30/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/30/2023 |
ATBPF Antibe Therapeutics | $0.22
| 8/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
ONCT Oncternal Therapeutics | $8.60
-3.9% | 4/3/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 4/3/2023 |
ONCT Oncternal Therapeutics | $8.60
-3.9% | 3/9/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/9/2023 |
DARE Daré Bioscience | $0.30
+3.5% | 2/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 2/14/2023 |
FUSN Fusion Pharmaceuticals | $21.25
+0.0% | 2/13/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/13/2023 |
ECOR electroCore | $5.64
+0.9% | 1/12/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
IMNN Imunon | $1.13
-0.9% | 11/14/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022 |
VXRT Vaxart | $0.84
-2.3% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022 |
OTLK Outlook Therapeutics | $8.29
-3.7% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $0.68
+3.0% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
LSTA Lisata Therapeutics | $2.85
+2.5% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
IMNN Imunon | $1.13
-0.9% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022 |
EDSA Edesa Biotech | $4.35
-1.1% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
ATE Antibe Therapeutics | C$0.30
| 8/15/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 8/15/2022 |
ARCT Arcturus Therapeutics | $26.32
-4.8% | 8/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22
| 6/30/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $1.42
+22.4% | 5/18/2022 | Target Raised by | Brookline Capital Management | Analyst Kumaraguru Raja | Buy -> Buy | $29.00 -> $31.00 | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $6.90
-2.3% | 3/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $21.32
-0.8% | 3/7/2022 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Hold -> Buy | $91.00 | High | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $56.16
+1.1% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | $143.00 | High | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $21.32
-0.8% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | | Low | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $3.91
| 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
BCDA BioCardia | $0.38
+2.7% | 2/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022 |
FUSN Fusion Pharmaceuticals | $21.25
+0.0% | 2/2/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/2/2022 |
ICCM IceCure Medical | $1.23
-4.7% | 2/1/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
This company has increased its dividend every year for 54 years (Ad) There are three basic steps to building the Ultimate Dividend Portfolio.
Step #1 is to Get The High Yields!
So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it.
But a company like Altria Group (MO) will. Click here to get them (for Free). |
DARE Daré Bioscience | $0.30
+3.5% | 1/19/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 1/19/2022 |
PROC Procaps Group | $2.60
-3.0% | 12/14/2021 | Reiterated by | Brookline Capital Management | Analyst Kemp Dolliver | Buy | $13.00 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 12/14/2021 |
KYMR Kymera Therapeutics | $35.12
+4.0% | 10/13/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | $80.00 | Medium | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $0.78
+5.4% | 9/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Hold | | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $1.42
+22.4% | 8/27/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $1.41
-0.7% | 8/24/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $6.91
+0.6% | 6/25/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | | High | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATE Antibe Therapeutics | C$0.30
| 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 6/3/2021 |
ATBPF Antibe Therapeutics | $0.22
| 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $0.68
+3.0% | 5/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $12.23
-1.8% | 5/7/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
ONCT Oncternal Therapeutics | $8.60
-3.9% | 3/30/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | $320.00 | High | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/30/2021 |
MRNA Moderna | $102.00
-1.4% | 2/26/2021 | Target Raised by | Brookline Capital Management | - | Buy | $180.00 -> $205.00 | Low | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
XFOR X4 Pharmaceuticals | $1.20
| 12/17/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $21.00 | High | View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020 |
VERU Veru | $1.42
+22.4% | 12/14/2020 | Target Raised by | Brookline Capital Management | Analyst K. Raja | | $13.00 -> $17.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
SYRS Syros Pharmaceuticals | $4.72
-7.6% | 11/10/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $190.00 | Low | View details for Brookline Capital Management rating of Syros Pharmaceuticals (NASDAQ:SYRS) on 11/10/2020 |
ECOR electroCore | $5.64
+0.9% | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $75.00 | Low | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
AWH Aspira Women's Health | $3.53
+1.1% | 10/14/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of Aspira Women’s Health (NASDAQ:AWH) on 10/14/2020 |
MEIP MEI Pharma | $3.25
-1.8% | 10/12/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020 |
DMTK DermTech | $0.59
| 9/11/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of DermTech (NASDAQ:DMTK) on 9/11/2020 |
FBRX Forte Biosciences | $0.78
+5.4% | 8/28/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $90.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
HUGE FSD Pharma | $0.46
| 8/20/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020 |
HUGE FSD Pharma | $0.46
| 8/20/2020 | Initiated by | Brookline Capital Management | - | Buy | $11.00 | N/A | View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020 |
KURA Kura Oncology | $17.68
-1.7% | 8/16/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Low | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $1.42
+22.4% | 8/14/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $26.32
-4.8% | 8/11/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
ATE Antibe Therapeutics | C$0.30
| 7/15/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 7/15/2020 |
MRNA Moderna | $102.00
-1.4% | 7/13/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | $95.00 | High | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.75
-3.8% | 6/3/2020 | Initiated by | Brookline Capital Management | - | Buy | $3.50 | Low | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
OTLK Outlook Therapeutics | $8.29
-3.7% | 5/5/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 5/5/2020 |
DARE Daré Bioscience | $0.30
+3.5% | 4/28/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $7.50 | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $4.35
-1.1% | 3/30/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $70.00 | High | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $5.39
-2.5% | 3/11/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $2.55
+2.0% | 3/13/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $5.39
-2.5% | 3/12/2020 | Initiated by | Brookline Capital Management | - | Buy | $15.00 | N/A | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $0.68
+3.0% | 2/19/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $42.00 | High | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $12.23
-1.8% | 2/4/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
BCDA BioCardia | $0.38
+2.7% | 11/26/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
BCDA BioCardia | $0.38
+2.7% | 11/26/2019 | Initiated by | Brookline Capital Management | - | Buy | $22.00 | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
MDNA Medicenna Therapeutics | C$1.67
-3.5% | 11/19/2019 | Reiterated by | Brookline Capital Management | - | Buy | C$4.00 | N/A | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
SCYX SCYNEXIS | $1.41
-0.7% | 8/19/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT Vaxart | $0.84
-2.3% | 8/15/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $6.00 | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019 |
VERU Veru | $1.42
+22.4% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
CLRB Cellectar Biosciences | $3.04
-5.3% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $60.00 -> $60.00 | High | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019 |
ARCT Arcturus Therapeutics | $26.32
-4.8% | 7/24/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
SCYX SCYNEXIS | $1.41
-0.7% | 1/4/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
CLRB Cellectar Biosciences | $3.04
-5.3% | 11/20/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018 |
ARCT Arcturus Therapeutics | $26.32
-4.8% | 9/27/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $0.16
| 7/27/2018 | Downgraded by | Brookline Capital Management | Analyst K. Raja | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $0.16
| 5/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |
Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (Ad) Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click!
Why This Report Is Your Gateway to Success:
* Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story.
* In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock.
(**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.) [Get Your Insights Now] |
